Clinical rapid evaluation of proprotein convertase subtilisin/kexin type 9 inhibitors for hypercholesterolemia
- VernacularTitle:PCSK9抑制剂用于高胆固醇血症的临床快速评价
- Author:
Xin YAO
1
;
Fengjiao KANG
1
;
Qinan YIN
2
;
Lizhu HAN
2
;
Yuan BIAN
2
Author Information
1. School of Medicine，University of Electronic Science and Technology of China，Chengdu 610054，China;Dept. of Pharmacy，Sichuan Academy of Medical Sciences，Sichuan Provincial People’s Hospital （Affiliated Hospital of University of Electronic Science and Technology of China）/Personalized Drug Research and Therapy Key Laboratory of Sichuan Province，Chengdu 610072，China
2. Dept. of Pharmacy，Sichuan Academy of Medical Sciences，Sichuan Provincial People’s Hospital （Affiliated Hospital of University of Electronic Science and Technology of China）/Personalized Drug Research and Therapy Key Laboratory of Sichuan Province，Chengdu 610072，China
- Publication Type:Journal Article
- Keywords:
PCSK9 inhibitors;
evolocumab;
tafolecimab
- From:
China Pharmacy
2026;37(2):149-154
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To conduct a clinical rapid evaluation of the marketed proprotein convertase subtilisin/kexin type 9 （PCSK9） inhibitors in China， including evolocumab， tafolecimab， recaticimab， ebronucimab， ongericimab and inclisiran. METHODS Based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions （second edition）， drug instructions， clinical diagnosis and treatment guidelines， and literature for six drugs were retrieved from CNKI， Wanfang Data， VIP， PubMed， Embase， Cochrane Library and related official websites. The clinical rapid evaluation was conducted from five aspects： pharmaceutical characteristics， effectiveness， safety， economy， and other attributes. RESULTS The pharmaceutical characteristics， effectiveness， safety， economy， other attributes， and total score of evolocumab scored 24， 27， 15.7， 10， 5.3， and 82 points， respectively. Tafolecimab scored 23.5， 23， 11.5， 9.97， 4.6， and 72.57 points， respectively. Recaticimab scored 20.5， 22， 15.5， 6.37， 3.5， and 67.87 points. Ebronucimab scored 20， 23， 11， 6.48， 3.5， and 63.98 points. Ongericimab scored 20.5， 23， 8.5， 4.83， 3.5， and 60.33 points. Inclisiran scored 25.5， 24， 13， 6.48， 5， and 73.98 points. CONCLUSIONS Evolocumab is the optimal choice for treating hypercholesterolemia and is recommended as the first-line option. Tafolecimab is the second-line option， and recaticimab is suitable for patients who are sensitive to drug adverse reactions. Inclisiran is suitable for patients with poor compliance. Ebronucimab and ongericimab are weakly recommended due to their later market introduction. Clinicians should make individualized drug selections based on factors such as patient risk level and compliance requirements.
